How China Is Rewriting the Rules Global Drug Development - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

How China Is Rewriting the Rules Global Drug Development

In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development

  • By

  • James Strachan

  • August 5, 2026

  • 16 min

Share

  • 1

    China's biopharma ecosystem has evolved from a generics-focused market to a globally influential engine for innovation and clinical development.

  • 2

    Regulatory reforms in China have significantly reduced drug approval timelines, enabling companies to obtain IND approval in about 30 working days.

  • 3

    China accounted for 32.3% of global drug-development program originations in 2024, with increasing partnerships from major pharma companies.

  • 4

    Chinese companies are recognized leaders in developing modalities like cell and gene therapy and antibody-drug conjugates, influencing global drug development.

  • 5

    China's integrated biopharma ecosystem promotes faster decision-making and efficiency, challenging traditional Western drug development assumptions.

Original Source(s)

How China Is Rewriting the Rules Global Drug Development

  • by James Strachan

  • August 5, 2026

Related Content

Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility

Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.

Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt) prospective cohort study